Editas Medicine (EDIT) said Tuesday it has achieved preclinical proof of concept for in vivo gene editing of hematopoietic stem cells in humanized mice to support the treatment of blood disorders like sickle cell disease and beta-thalassemia.
The company also said it is exploring options to partner or out-license its reni-cel program, a cell therapy for sickle cell disease and beta-thalassemia, to reduce future costs and support further development.
Price: 3.56, Change: -0.21, Percent Change: -5.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.